Is Higher Dose of Inhaled Treprostinil Truly Superior to Lower Dose of Inhaled Treprostinil in Patients With Pulmonary Hypertension Associated With Interstitial Lung Diseases?

Chest. 2024 May;165(5):e161. doi: 10.1016/j.chest.2023.12.032.
No abstract available

Publication types

  • Editorial
  • Letter

MeSH terms

  • Administration, Inhalation
  • Antihypertensive Agents* / administration & dosage
  • Antihypertensive Agents* / therapeutic use
  • Dose-Response Relationship, Drug
  • Epoprostenol* / administration & dosage
  • Epoprostenol* / analogs & derivatives
  • Humans
  • Hypertension, Pulmonary* / drug therapy
  • Lung Diseases, Interstitial* / complications
  • Lung Diseases, Interstitial* / drug therapy

Substances

  • Epoprostenol
  • treprostinil
  • Antihypertensive Agents